Hot Features
Überwachen Sie mehrere Echtzeitkurse von führenden Börsen wie NASDAQ, NYSE, AMEX, Bovespa und mehr.
| Datum | Name des Inhabers | Gehandelte Aktien | Wertspanne ($) | Transaktionstyp | Preisspanne ($) | Aktien am Meldungsende | % Veränderung |
|---|---|---|---|---|---|---|---|
| 2026-05-01 | Mr. Adam KeeneyExec. VP & Head of Corporate Development | -455,00 | 85,11k | Derivative Exercise and Sale | 187,06 | 6,37k | - |
| 2026-05-01 | Mr. Adam KeeneyExec. VP & Head of Corporate Development | 484,00 | 0,00 | Derivative Exercise and Retained Stock | - | 6,37k | 8,23% |
| 2026-04-01 | Mr. Sean GodboutVP, CAO & Global Corporate Controller | -54,00 | 9,92k | Derivative Exercise and Sale | 183,78 | 1,34k | - |
| 2026-04-01 | Mr. Sean GodboutVP, CAO & Global Corporate Controller | 127,00 | 0,00 | Derivative Exercise and Retained Stock | - | 1,34k | 10,45% |
| 2026-02-12 | Ms. Nicole MurphyExec. VP and Head of Pharmaceutical Operations & Technology | 3,00 | 585,11 | Kauf | 195,04 | 19,61k | 0,02% |
| 2026-02-06 | Mr. Christopher A. ViehbacherPresident, CEO & Director | 13,48k | 0,00 | Derivative Exercise and Retained Stock | - | 29,92k | 81,99% |
| 2026-02-06 | Mr. Christopher A. ViehbacherPresident, CEO & Director | -10,98k | 2,21M | Derivative Exercise and Sale | 201,18 | 29,92k | - |
| 2026-02-06 | Dr. Priya SinghalExec. VP & Head of Development | 1,77k | 0,00 | Derivative Exercise and Retained Stock | - | 8,04k | 28,26% |
| 2026-02-06 | Dr. Priya SinghalExec. VP & Head of Development | -5,13k | 1,03M | Derivative Exercise and Sale | 199,83 - 201,18 | 8,04k | - |
| 2026-02-06 | Ms. Nicole MurphyExec. VP and Head of Pharmaceutical Operations & Technology | 5,39k | 0,00 | Derivative Exercise and Retained Stock | - | 19,61k | 37,87% |
| 2026-02-06 | Ms. Nicole MurphyExec. VP and Head of Pharmaceutical Operations & Technology | -3,34k | 671,74k | Derivative Exercise and Sale | 201,18 | 19,61k | - |
| 2026-02-06 | Ms. Robin C. KramerExec. VP & CFO | 3,46k | 0,00 | Derivative Exercise and Retained Stock | - | 11,47k | 43,19% |
| 2026-02-06 | Ms. Robin C. KramerExec. VP & CFO | -1,54k | 310,42k | Derivative Exercise and Sale | 201,18 | 11,47k | - |
| 2026-02-06 | Mr. Adam KeeneyExec. VP & Head of Corporate Development | 3,50k | 0,00 | Derivative Exercise and Retained Stock | - | 5,88k | 146,69% |
| 2026-02-06 | Mr. Adam KeeneyExec. VP & Head of Corporate Development | -1,58k | 318,47k | Derivative Exercise and Sale | 201,18 | 5,88k | - |
| 2026-02-06 | Mr. Rachid IzzarExec. VP and Head of Global Product Strategy & Commercialization | 4,85k | 0,00 | Derivative Exercise and Retained Stock | - | 11,01k | 78,75% |
| 2026-02-06 | Mr. Rachid IzzarExec. VP and Head of Global Product Strategy & Commercialization | -2,04k | 410,00k | Derivative Exercise and Sale | 201,18 | 11,01k | - |
| 2026-02-06 | Dr. Jane GroganExec. VP & Head of Research | 2,27k | 0,00 | Derivative Exercise and Retained Stock | - | 4,06k | 126,58% |
| 2026-02-06 | Dr. Jane GroganExec. VP & Head of Research | -991,00 | 199,37k | Derivative Exercise and Sale | 201,18 | 4,06k | - |
| 2026-02-06 | Dr. Ginger GregoryExec. VP & Chief HR Officer | 4,59k | 0,00 | Derivative Exercise and Retained Stock | - | 22,36k | 25,86% |
| 2026-02-06 | Dr. Ginger GregoryExec. VP & Chief HR Officer | -2,59k | 520,86k | Derivative Exercise and Sale | 201,18 | 22,36k | - |
| 2026-02-06 | Mr. Sean GodboutVP, CAO & Global Corporate Controller | 720,00 | 0,00 | Derivative Exercise and Retained Stock | - | 1,22k | 145,45% |
| 2026-02-06 | Mr. Sean GodboutVP, CAO & Global Corporate Controller | -359,00 | 72,22k | Derivative Exercise and Sale | 201,18 | 1,22k | - |
| 2026-02-06 | Ms. Susan H. AlexanderInsider | 5,54k | 0,00 | Derivative Exercise and Retained Stock | - | 61,89k | 9,84% |
| 2026-02-06 | Ms. Susan H. AlexanderInsider | -3,50k | 704,93k | Derivative Exercise and Sale | 201,18 | 61,89k | - |
| 2026-01-30 | Dr. Priya SinghalExec. VP & Head of Development | 499,00 | 0,00 | Derivative Exercise and Retained Stock | - | 6,27k | 8,65% |
| 2026-01-30 | Dr. Priya SinghalExec. VP & Head of Development | -1,33k | 238,81k | Derivative Exercise and Sale | 179,30 - 179,89 | 6,27k | - |
| 2025-12-01 | Mr. Christopher A. ViehbacherPresident, CEO & Director | 3,64k | 0,00 | Derivative Exercise and Retained Stock | - | 16,44k | 28,39% |
| 2025-12-01 | Mr. Christopher A. ViehbacherPresident, CEO & Director | -3,40k | 605,16k | Derivative Exercise and Sale | 177,78 | 16,44k | - |
| 2025-10-31 | Dr. Jane GroganExec. VP & Head of Research | 358,00 | 0,00 | Derivative Exercise and Retained Stock | - | 1,79k | 24,98% |
| 2025-10-31 | Dr. Jane GroganExec. VP & Head of Research | -337,00 | 51,99k | Derivative Exercise and Sale | 154,27 | 1,79k | - |
| 2025-10-02 | Mr. Sean GodboutVP, CAO & Global Corporate Controller | 18,00 | 0,00 | Derivative Exercise and Retained Stock | - | 495,00 | 3,77% |
| 2025-10-02 | Mr. Sean GodboutVP, CAO & Global Corporate Controller | -8,00 | 1,24k | Derivative Exercise and Sale | 155,25 | 495,00 | - |
| 2025-08-29 | Dr. Priya SinghalExec. VP & Head of Development | 345,00 | 0,00 | Derivative Exercise and Retained Stock | - | 5,77k | 6,36% |
| 2025-08-29 | Dr. Priya SinghalExec. VP & Head of Development | -1,32k | 175,75k | Derivative Exercise and Sale | 132,22 - 133,55 | 5,77k | - |
| 2025-07-08 | Mr. Rachid IzzarExec. VP and Head of Global Product Strategy & Commercialization | -2,22k | 300,11k | Verkauf | 135,00 | 6,33k | -25,99% |
Die zuletzt besuchten Aktien werden in diesem Feld angezeigt, so dass Sie leicht zu den Aktien zurückkehren können, die Sie zuvor angesehen haben.
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Mit E-Mail registrieren
Haben Sie schon ein Konto? Anmelden
Haben Sie kein Konto? Registrieren
Durch die Registrierung bestätige ich, dass ich die Allgemeinen Geschäftsbedingungen von ADVFN gelesen und verstanden habe und ihnen zustimme und dass ich ein Privatinvestor bin.
Premium
